ASX - By Stock
|
CSL |
Re:
Ann: Shareholder Information Meetings
|
|
W534220
|
7 |
2.8K |
2 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
7
|
2.8K
|
2
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Shareholder Information Meetings
|
|
W534220
|
7 |
2.8K |
1 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
7
|
2.8K
|
1
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 1Q24 APRA lodgement and trading update
|
|
W534220
|
2 |
548 |
2 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
2
|
548
|
2
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
2 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
51
|
24K
|
2
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
4 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
51
|
24K
|
4
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
0 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
51
|
24K
|
0
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
0 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
51
|
24K
|
0
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
1 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
51
|
24K
|
1
|
|
ASX - By Stock
|
CSL |
Re:
News: CSL Ferinject Approved By Health Canada For The Treatment Of Iron Deficiency Anemia In Adult...
|
|
W534220
|
5 |
3.3K |
4 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
5
|
3.3K
|
4
|
|
ASX - By Stock
|
CSL |
Re:
News: CSL Ferinject Approved By Health Canada For The Treatment Of Iron Deficiency Anemia In Adult...
|
|
W534220
|
5 |
3.3K |
0 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
5
|
3.3K
|
0
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
5 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
112
|
33K
|
5
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
3 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
112
|
33K
|
3
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
8 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
112
|
33K
|
8
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
1 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
112
|
33K
|
1
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
4 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
112
|
33K
|
4
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
1 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
112
|
33K
|
1
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
1 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
112
|
33K
|
1
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
112
|
33K
|
0
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
2 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
112
|
33K
|
2
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
2 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
112
|
33K
|
2
|
|
ASX - By Stock
|
HLI |
Re:
Ann: Appendix 4E
|
|
W534220
|
14 |
3.3K |
1 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
14
|
3.3K
|
1
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
3 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
112
|
33K
|
3
|
|
ASX - By Stock
|
HLI |
Re:
Ann: Appendix 4E
|
|
W534220
|
14 |
3.3K |
0 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
14
|
3.3K
|
0
|
|
ASX - By Stock
|
HLI |
Re:
Ann: 2023 Full Year Results Investor Presentation
|
|
W534220
|
112 |
33K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
112
|
33K
|
5
|
|
ASX - By Stock
|
HLI |
Re:
Ann: Appendix 4E
|
|
W534220
|
14 |
3.3K |
0 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
14
|
3.3K
|
0
|
|
ASX - By Stock
|
OVT |
Re:
OVANTI LIMITED 2024 AND BEYOND!
|
|
W534220
|
127 |
45K |
2 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
127
|
45K
|
2
|
|
ASX - By Stock
|
OVT |
Re:
OVANTI LIMITED 2024 AND BEYOND!
|
|
W534220
|
127 |
45K |
1 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
127
|
45K
|
1
|
|
ASX - By Stock
|
OVT |
Re:
OVANTI LIMITED 2024 AND BEYOND!
|
|
W534220
|
127 |
45K |
1 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
127
|
45K
|
1
|
|
ASX - By Stock
|
OVT |
Re:
OVANTI LIMITED 2024 AND BEYOND!
|
|
W534220
|
127 |
45K |
0 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
127
|
45K
|
0
|
|
ASX - By Stock
|
HLI |
Re:
Propriety prices reclaim all declines
|
|
W534220
|
26 |
7.8K |
6 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
26
|
7.8K
|
6
|
|
ASX - By Stock
|
OVT |
Re:
OVANTI LIMITED 2024 AND BEYOND!
|
|
W534220
|
127 |
45K |
3 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
127
|
45K
|
3
|
|
ASX - By Stock
|
CSL |
Growth
|
|
W534220
|
1 |
1.1K |
7 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
1
|
1.1K
|
7
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Half Year Results Investor Presentation
|
|
W534220
|
18 |
9.3K |
4 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
18
|
9.3K
|
4
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Statutory Accounts for the Half Year Ended 31 December 2023
|
|
W534220
|
52 |
25K |
6 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
52
|
25K
|
6
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Statutory Accounts for the Half Year Ended 31 December 2023
|
|
W534220
|
52 |
25K |
6 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
52
|
25K
|
6
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Statutory Accounts for the Half Year Ended 31 December 2023
|
|
W534220
|
52 |
25K |
3 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
52
|
25K
|
3
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Half Year Results Investor Presentation
|
|
W534220
|
18 |
9.3K |
7 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
18
|
9.3K
|
7
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Half Year Results Investor Presentation
|
|
W534220
|
18 |
9.3K |
3 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
18
|
9.3K
|
3
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Statutory Accounts for the Half Year Ended 31 December 2023
|
|
W534220
|
52 |
25K |
8 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
52
|
25K
|
8
|
|
ASX - By Stock
|
CSL |
Re:
News: CSL CSL Says Top-Line Results From Phase 3 Aegis-II Trial Evaluating Efficacy And Safety Of...
|
|
W534220
|
2 |
857 |
3 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
2
|
857
|
3
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
0 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
51
|
24K
|
0
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
1 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
51
|
24K
|
1
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
1 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
51
|
24K
|
1
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
0 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
51
|
24K
|
0
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
2 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
51
|
24K
|
2
|
|
ASX - By Stock
|
CSL |
Re:
Csl112
|
|
W534220
|
27 |
10K |
0 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
27
|
10K
|
0
|
|
ASX - By Stock
|
CSL |
Re:
Csl112
|
|
W534220
|
27 |
10K |
1 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
27
|
10K
|
1
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Top-line Results from the Phase 3 AEGIS-II Trial
|
|
W534220
|
51 |
24K |
0 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
51
|
24K
|
0
|
|
ASX - By Stock
|
CSL |
Re:
Csl112
|
|
W534220
|
27 |
10K |
0 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
27
|
10K
|
0
|
|
ASX - By Stock
|
CSL |
Re:
Csl112
|
|
W534220
|
27 |
10K |
2 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
27
|
10K
|
2
|
|